AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions of claims in the application:

Listing of Claims:

1-30. (Cancelled)

31. (Currently amended) A method for ~~the discrimination between~~ detecting von-Willebrand disease (vWD) ~~type 1 and type 2~~ comprising the steps of:
(a) detecting ~~vWF activity in a test sample according to the method for detecting~~ von-Willebrand factor (vWF) activity ~~comprising assaying~~ in a sample ~~in the presence of~~ comprising a soluble form or a portion of glycoprotein ~~I~~Ib(α) (GPIb(α)) and ristocetin[[,]] or a functionally equivalent substance;[[.]]
(b) determining the amount of vWF-antigen in said ~~test~~ sample;
(c) determining the ratio between vWF-activity and vWF-antigen for said ~~test~~ sample; ~~and~~
(d) comparing the ~~under (c) obtained~~ ratio obtained under (c) to ~~the~~ a range of ratios established as normal range; and
(e) detecting von-Willebrand disease based on the comparison result obtained under step (d).

32. (Currently amended) The method of claim 31, wherein ~~said detection of~~ detecting von-Willebrand factor (vWF) activity under step (a) ~~is carried out by~~ comprises detecting the formation of a complex of vWF and GPIb(α) ~~and/or a formed complex of vWF and GPIb(α)~~.

33. (Currently amended) The method of claim 31, wherein said GPIb(α) is bound to a solid support.

34. (Currently amended) The method of claim 3~~3~~1, wherein said GPIb(α) is bound to said solid support by an ~~specifically reacting~~ anti-GPIb(α) antibody.

35. (Currently amended) The method of claim 3~~2~~1, wherein ~~detection of von-Willebrand factor (vWF) activity is carried out by detecting the formation of a complex of vWF and GPIb(α)~~

~~and/or a formed complex of vWF and GPIb(α) and wherein~~ said complex is bound to a solid support.

36. (Currently amended) The method of claim 3~~5~~1, wherein ~~detection of von Willebrand factor (vWF) activity is carried out by detecting the formation of a complex of vWF and GPIb(α) and/or a formed complex of vWF and GPIb and wherein~~ said complex is bound to a solid support by a~~n~~ ~~specifically reacting~~ anti-GPIb(α) antibody, by a~~n~~ ~~specifically reacting~~ anti-vWF antibody, by a~~n~~ ~~specifically reacting~~ anti-Factor VIII antibody ~~and/~~or by collagen.

37. (Currently amended) The method of claim 31, wherein ~~said detection is carried out by~~ detecting vWF activity under step (a) comprises using a~~n~~ ~~specifically reacting~~ anti-vWF antibody, ~~by~~ a~~n~~ ~~specifically reacting~~ anti-Factor VIII antibody, ~~by~~ a~~n~~ ~~specifically reacting~~ anti-GPIb ~~a~~(α) antibody, ~~by~~ a collagen ~~and/~~or mixtures thereof.

38. (Currently amended) The method of claim 31, wherein ~~said detection is carried out by~~ detecting vWF activity under step (a) comprises using ~~an~~ heterogeneous or ~~by~~ ~~an~~ homogeneous assay.

39. (Currently amended) The method of claim 3~~8~~1, wherein ~~said detection is carried out by~~ detecting vWF activity under step (a) comprises using ~~an~~ heterogeneous assay selected from the group consisting of linked immuno sorbent assay (ELISA), a radioimmunoassay (RIA), an immuno radio metric assay (IRMA), a fluorescent immunoassay (FlA), a chemiluminescent immuno assay (CLlA) ~~or~~ and an electro chemiluminescent immuno assay (ECL).

40. (Currently amended) The method of claim 3~~8~~1, wherein ~~said detection is carried out by~~ detecting vWF activity under step (a) comprises using ~~an~~ homogeneous agglutination assay.

41. (Currently amended) The method of claim 31, wherein the sample is obtained from ~~selected from the group of a diluted or undiluted~~ blood, ~~or~~ serum or plasma of a patient ~~sample~~.

42-45. (Canceled)

46. (Withdrawn-currently amended) A kit for ~~the discrimination between~~ detecting von-Willebrand disease (vWD) ~~type 1 and type 2~~ comprising ~~at least one of the following~~:
(a) a soluble form or a portion of glycoprotein Ib (α) (GPIb(α));
(b) a ristocetin, or a functional equivalent substance; and
~~(c) an antibody selected from the group of a specifically reacting anti-GPIb a specifically reacting anti-vWF antibody and a specifically reacting anti-Factor VIII antibody~~
(~~d~~c) a solid support.

47. (Withdrawn-currently amended) ~~A~~The kit ~~according to~~ of claim 46, wherein the said soluble form or the portion of glycoprotein Ib (α) (GPIb(α)) is a recombinant protein.

48. (New) The method of claim 31, wherein detecting von-Willebrand disease under step (e) comprises discriminating between different types of von-Willebrand disease.

49. (New) The method of claim 48, wherein detecting von-Willebrand disease under step (e) comprises discriminating between von-Willebrand disease type 1 and type 2.

50. (New) The method of claim 31, wherein the soluble form or the portion of glycoprotein 1b(α) (GPIb(α)) is a recombinant protein.

51. (New) The method of claim 37, wherein said antibody is a monoclonal antibody, a polyclonal antibody, a synthetic antibody, or a fragment of an antibody.

52. (New) The method of claim 37, wherein said antibody or said collagen is detectably labeled.

53. (New) The method of claim 35, wherein said solid support is selected from a group consisting of plastic, glass, silicon, metal, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amylose, natural or modified cellulose, polyacrylamide, agarose, magnetide and any combinations thereof.

54. (New) The method of claim 53, wherein said solid support comprises a latex bead.

55. (New) The method of claim 40, wherein said agglutination is measured by electric field variation, magnetic field variation, turbidimetric variation or light scattering.

56. (New) The method of claim 41, wherein the sample is diluted.

57. (New) The method of claim 31, wherein detecting vWF activity under step (a) comprises detecting a formed complex of vWF and GPlb(α).

58. (New) The method of claim 57, wherein said complex is bond to a solid support.

59. (New) The method of claim 58, wherein said complex is bound to a solid support by an anti-GPlb(α) antibody, by an anti-vWF antibody, by an anti-Factor VIII antibody or by collagen.